The role of local estrogen therapy in the management of pelvic floor disorders

References

• Wu JM, Vaughan CP, Goode PS, et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol 2014;123:141–8
   PubMed Web of Science ®Google Scholar
• Rahn DD, Ward RM, Sanses TV, et al.; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J 2015;26:3–13
   PubMed Web of Science ®Google Scholar
• Swift S, Woodman P, O'Boyle A, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol 2005;192:795–806
   PubMed Web of Science ®Google Scholar
• Luber KM, Boero S, Choe JY. The demographics of pelvic floor disorders: current observations and future projections. Am J Obstet Gynecol 2001;184:1496–501
   PubMed Web of Science ®Google Scholar
• Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int 2013;19:155–62
   PubMedGoogle Scholar
• Zbucka-Kretowska M, Marcus-Braun N, Eboue C, et al. Expression of estrogen receptors in the pelvic floor of pre- and post-menopausal women presenting pelvic organ prolapse. Folia Histochem Cytobiol 2011;49:521–7
   PubMed Web of Science ®Google Scholar
• Sung VW, Washington B, Raker CA. Costs of ambulatory care related to female pelvic floor disorders in the United States. Am J Obstet Gynecol 2010;202:483.e1–4
   Google Scholar
• Longcope C. Metabolic clearance and blood production rates of estrogens in postmenopausal women. Am J Obstet Gynecol 1971;111:778–81
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
   PubMed Web of Science ®Google Scholar
• Pessina MA, Hoyt RF Jr, Goldstein I, Traish AM. Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology 2006;147:61–9
   PubMed Web of Science ®Google Scholar
• Kim NN, Min K, Pessina MA, Munarriz R, Goldstein I, Traish AM. Effects of ovariectomy and steroid hormones on vaginal smooth muscle contractility. Int J Impot Res 2004;16:43–50
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim NN, Jeong SJ, Munarriz R, Goldstein I, Traish AM. Modulation of rat vaginal blood flow and estrogen receptor by estradiol. J Urol 2004;172:1538–43
   PubMed Web of Science ®Google Scholar
• Goldstein I, Dicks B, Kim NN, Hartzell R. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med 2013;1:44–53
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37–49
   PubMed Web of Science ®Google Scholar
• Rud T, Andersson KE, Asmussen M, Hunting A, Ulmsten U. Factors maintaining the intraurethral pressure in women. Inv Urol 1980;17:343–7
   PubMedGoogle Scholar
• Iosif CS, Batra S, Ek A, Asted B. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol 1981;141:817–20
   PubMed Web of Science ®Google Scholar
• Versi E, Cardozo LD. Urethral vascular pulsations. Proc Int Cont Soc 1985;15:503–94
   Google Scholar
• Endo RM, Girão MJBC, Sartori MGF, Simões MJ, Baracat EC, Rodrigues de Lima J. Effects of estrogen–progestogen hormonal replacement therapy on periurethral and bladder vessels. Int Urogynecol J 2000;11:120–3
   PubMed Web of Science ®Google Scholar
• Kobata SA, Girão MJ, Baracat EC, et al. Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Doppler velocimetry analysis. Maturitas 2008;61:243–7
   PubMed Web of Science ®Google Scholar
• Jármy-Di Bella Z, Girão MJ, Di Bella V, et al. Hormonal influence on periurethral vessels in postmenopausal incontinent women using Doppler velocimetry analysis. Maturitas 2007;56:297–302
   PubMed Web of Science ®Google Scholar
• Gebhart JB, Rickard DJ, Barrett TJ, et al. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol 2001;185:1325–30
   PubMed Web of Science ®Google Scholar
• Xie Z, Shi H, Zhou C, Dong M, Hong L, Jin H. Alterations of estrogen receptor-alpha and -beta in the anterior vaginal wall of women with urinary incontinence. Eur J Obstet Gynecol Reprod Biol 2007;134:254–8
   PubMed Web of Science ®Google Scholar
• Mulholland SG, Qureshi SM, Fritz RW, Silverman H. Effect of hormonal deprivation on the bladder defense mechanism. J Urol 1982;127:1010–13
   PubMed Web of Science ®Google Scholar
• Skala CE, Petry IB, Albrich SB, Puhl A, Naumann G, Koelbl H. The effect of hormonal status on the expression of estrogen and progesterone receptor in vaginal wall and periurethral tissue in urogynecological patients. Eur J Obstet Gynecol Reprod Biol 2010;153:99–103
   PubMed Web of Science ®Google Scholar
• Söderberg MW, Johansson B, Masironi B, et al. Pelvic floor sex steroid hormone receptors, distribution and expression in pre- and postmenopausal stress urinary incontinent women. Acta Obstet Gynecol Scand 2007;86:1377–84
   PubMed Web of Science ®Google Scholar
• Taylor AH, Guzail M, Al-Azzawi F. Differential expression of oestrogen receptor isoforms and androgen receptor in the normal vulva and vagina compared with vulval lichen sclerosus and chronic vaginitis. Br J Dermatol 2008;158:319–28
   PubMed Web of Science ®Google Scholar
• Skala CE, Petry IB, Albrich S, Puhl A, Naumann G, Koelbl H. The effect of genital and lower urinary tract symptoms on steroid receptor expression in women with genital prolapse. Int Urogynecol J 2011;22:705–12
   PubMed Web of Science ®Google Scholar
• Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 2006;103:13162–7
   PubMed Web of Science ®Google Scholar
• Ting AY, Blacklock AD, Smith PG. Estrogen regulates vaginal sensory and autonomic nerve density in the rat. Biol Reprod 2004;71:1397–404
   PubMed Web of Science ®Google Scholar
• Zoubina EV, Mize AL, Alper RH, Smith PG. Acute and chronic estrogen supplementation decreases uterine sympathetic innervation in ovariectomized adult virgin rats. Histol Histopathol 2001;16:989–96
   PubMed Web of Science ®Google Scholar
• Levin RM, Jacobowitz D, Wein AJ. Autonomic innervation of rabbit urinary bladder following estrogen administration. Urology 1981;17:449–53
   PubMed Web of Science ®Google Scholar
• Batra S, Andersson KE. Oestrogen-induced changes in muscarinic receptor density and contractile responses in the female rabbit urinary bladder. Acta Physiol Scand 1989;137:135–41
   PubMedGoogle Scholar
• Valeri A, Brain KL, Young JS, Sgaragli G, Pessina F. Effects of 17beta-oestradiol on rat detrusor smooth muscle contractility. Exp Physiol 2009;94:834–46
   PubMed Web of Science ®Google Scholar
• Ning N, Lin G, Lue TF, Lin CS. Effects of estrogen, raloxifene, and levormeloxifene on the expression of Rho-kinase signaling molecules in urethral smooth muscle cells. Urology 2010;76:1517.e6–11
   Google Scholar
• Bernstein IT. The pelvic floor muscles: muscle thickness in healthy and urinary-incontinent women measured by perineal ultrasonography with reference to the effect of pelvic floor training. Estrogen receptor studies. Neurourol Urodyn 1997;16:237–75
   PubMed Web of Science ®Google Scholar
• Malone L, Schuler C, Leggett RE, Levin RM. Effect of estrogen and ovariectomy on response of the female rabbit urinary bladder to two forms of in vitro oxidative stress. Int Urogynecol J 2014;25:791–8
   PubMed Web of Science ®Google Scholar
• Ibe C, Simon JA. Vulvovaginal atrophy: current and future therapies (CME). J Sex Med 2010;7:1042–50
   PubMed Web of Science ®Google Scholar
• Lev-Sagie A. Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. Clin Obstet Gynecol 2015;58:476–91
   PubMed Web of Science ®Google Scholar
• Lindahl SH. Reviewing the options for local estrogen treatment of vaginal atrophy. Int J Womens Health 2014;6:307–12
   PubMedGoogle Scholar
• Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 2012;19:109–17
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053–60
   PubMed Web of Science ®Google Scholar
• Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. J Sex Med 2008;5:132–8
   PubMed Web of Science ®Google Scholar
• Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009;12:91–105
   PubMed Web of Science ®Google Scholar
• Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
   PubMed Web of Science ®Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;(4):CD001500
   Google Scholar
• North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355–69
   PubMed Web of Science ®Google Scholar
• Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M. Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy. Climacteric 2010;13:228–37
   PubMed Web of Science ®Google Scholar
• Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med 2005;2(Suppl 3):154–65
   PubMed Web of Science ®Google Scholar
• Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand 1984;63:257–60
   PubMed Web of Science ®Google Scholar
• Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA 2014;311:844–54
   PubMed Web of Science ®Google Scholar
• Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000;10:509–15
   PubMed Web of Science ®Google Scholar
• Hu KK, Boyko EJ, Scholes D, et al. Risk factors for urinary tract infections in postmenopausal women. Arch Intern Med 2004;164:989–93
   PubMed Web of Science ®Google Scholar
• Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Obstet Gynecol 2008;112:689–90
   PubMed Web of Science ®Google Scholar
• Raz R, Colodner R, Rohana Y, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis 2003;36:1362–8
   PubMed Web of Science ®Google Scholar
• Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999;180:1072–9
   PubMed Web of Science ®Google Scholar
• Geerlings SE, Beerepoot MA, Prins JM. Prevention of recurrent urinary tract infections in women: antimicrobial and nonantimicrobial strategies. Infect Dis Clin North Am 2014;28:135–47
   PubMed Web of Science ®Google Scholar
• Lüthje P, Hirschberg AL, Brauner A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas 2014;77:32–6
   PubMed Web of Science ®Google Scholar
• Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753–6
   PubMed Web of Science ®Google Scholar
• Revicky V, Tincello DG. New surgical approaches for urinary incontinence in women. Maturitas 2014;77:239–42
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, et al.; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4–20
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306–14
   PubMed Web of Science ®Google Scholar
• Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012;10:CD001405
   Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327–36
   PubMed Web of Science ®Google Scholar
• Smith AL, Wein AJ. Estrogen replacement therapy for the treatment of postmenopausal genitourinary tract dysfunction. Discov Med 2010;10:500–10
   PubMedGoogle Scholar
• Robinson D, Cardozo L, Milsom I, et al. Oestrogens and overactive bladder. Neurourol Urodyn 2014;33:1086–91
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand 2004;83:892–7
   PubMed Web of Science ®Google Scholar
• Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril 2006;85:155–60
   PubMed Web of Science ®Google Scholar
• Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 2000;107:1029–34
   PubMed Web of Science ®Google Scholar
• Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women–a double-blind placebo-controlled study. J Obstet Gynaecol 2001;21:383–5
   PubMedGoogle Scholar
• Simunić V, Banović I, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003;82:187–97
   PubMed Web of Science ®Google Scholar
• Geoffrion R; Society of Obstetricians and Gynaecologists of Canada. Treatments for overactive bladder: focus on pharmacotherapy. J Obstet Gynaecol Can 2012;34:1092–101
   PubMedGoogle Scholar
• Rembratt A. Editorial comment on: Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol 2009;55:719
   PubMedGoogle Scholar
• Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology 2003;62:45–51
   PubMed Web of Science ®Google Scholar
• Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Database Syst Rev 2010;9:CD007063
   PubMed Web of Science ®Google Scholar
• Diwadkar GB, Barber MD, Feiner B, Maher C, Jelovsek JE. Complication and reoperation rates after apical vaginal prolapse surgical repair: a systematic review. Obstet Gynecol 2009;113:367–73
   PubMed Web of Science ®Google Scholar
• Maher C, Baessler K, Glazener CM, Adams EJ, Hagen S. Surgical management of pelvic organ prolapse in women: a short version Cochrane review. Neurourol Urodyn 2008;27:3–12
   PubMed Web of Science ®Google Scholar
• Denman MA, Gregory WT, Boyles SH, Smith V, Edwards SR, Clark AL. Reoperation 10 years after surgically managed pelvic organ prolapse and urinary incontinence. Am J Obstet Gynecol 2008;198:555.e1–5
   Google Scholar
• Mikkelsen AL, Felding C, Clausen HV. Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecol Obstet Invest 1995;40:125–8
   PubMed Web of Science ®Google Scholar
• Rahn DD, Good MM, Roshanravan SM, et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. J Clin Endocrinol Metab 2014;99:3728–36
   PubMed Web of Science ®Google Scholar
• Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002;9:179–87
   PubMed Web of Science ®Google Scholar
• Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 μg 17α-estradiol vaginal tablets. Climacteric 2010;13:219–27
   PubMed Web of Science ®Google Scholar
• Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195–7
   PubMed Web of Science ®Google Scholar
• Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women’s Midlife Health Project. Climacteric 2004;7:375–89
   PubMed Web of Science ®Google Scholar
• Vaccaro CM, Mutema GK, Fellner AN, et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Med Reconstr Surg 2013;19:34–9
   PubMed Web of Science ®Google Scholar
• Grady D, Vittinghoff E, Lin F, et al. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Menopause 2007;14:391–6
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012;13:476–86
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21367s002lbl.pdf
   Google Scholar
• http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020472s007lbl.pdf
   Google Scholar
• http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020908s017lbl.pdf
   Google Scholar
• http://medlibrary.org/lib/rx/meds/estrace-3/
   Google Scholar
• http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020527s037lbl.pdf
   Google Scholar
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015;100:3975–4011
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009;16:719–27
   PubMed Web of Science ®Google Scholar
• Luengratsameerung S, Panyakhamlerd K, Treratanachat S, Taechakraichana N. Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women. Climacteric 2013;16:133–40
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116:876–83
   PubMed Web of Science ®Google Scholar
• Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83–92
   PubMed Web of Science ®Google Scholar
• Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996;174:85–92
   PubMed Web of Science ®Google Scholar
• Portman D, Shulman L, Yeaw J, et al. One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy. Menopause 2015;22:1197–203
   PubMed Web of Science ®Google Scholar
• Mattsson LÅ, Ericsson Å, Bøgelund M, Maamari R. Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy. Maturitas 2013;74:259–63
   PubMed Web of Science ®Google Scholar
• Shulman LP, Portman DJ, Lee WC, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. J Womens Health (Larchmt) 2008;17:569–78
   PubMed Web of Science ®Google Scholar
• Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 2003;102:823–34
   PubMed Web of Science ®Google Scholar